fbpx

Day

November 11, 2014
Proceeds to enable clinical Phase 2 Proof-of-Concept studies for two lead compounds - a histamine H4 receptor antagonist for atopic dermatitis and a topical cPLA2 inhibitor for psoriasis

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge